DiaSorin Stock Forecast, Price & News

+14.92 (+9.00 %)
(As of 04/13/2021 12:00 AM ET)
Today's Range
Now: $180.73
50-Day Range
MA: $186.55
52-Week Range
Now: $180.73
Volume1 shs
Average Volume279 shs
Market Capitalization$10.11 billion
P/E Ratio50.34
Dividend YieldN/A
DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics tests for private and hospital microbiology laboratories worldwide. The company offers testing kits for infectious diseases, such as gastrointestinal infections, bone and mineral metabolism, endocrinology, hypertension, oncology, onco-hematology, and autoimmunity. It also provides various immunodiagnostic platforms, including LIAISON XL, LIAISON XS, LIAISON QuantiFERON TB Gold PLUS, LIAISON Elastase-1, and LIAISON MDX. The company sells its products directly, as well as through an international network of independent distributors. DiaSorin S.p.A. has collaboration with QIAGEN to develop an ultra-sensitive diagnostic test for Lyme disease. The company was founded in 1968 and is headquartered in Saluggia, Italy.
DiaSorin logo

Industry, Sector and Symbol

Industry Private households
Year FoundedN/A



Sales & Book Value

Annual Sales$791.17 million
Cash Flow$4.22 per share
Book Value$16.99 per share



Market Cap$10.11 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableNot Optionable


DiaSorin To Buy Luminex For $1.8 Bln
April 12, 2021 |  markets.businessinsider.com
DiaSorin S.p.A. reports FY results
March 11, 2021 |  seekingalpha.com
DiaSorin Weighs Diagnostics Deal for Luminex
February 25, 2021 |  msn.com
Diasorin S.p.A. (DSRLF)
October 16, 2020 |  nasdaq.com
InMode (INMD) Surges: Stock Moves 10.6% Higher
July 14, 2020 |  finance.yahoo.com
See More Headlines


Overall MarketRank

0.78 out of 5 stars

Medical Sector

1205th out of 2,019 stocks

Private Households Industry

208th out of 378 stocks

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
+14.92 (+9.00 %)
(As of 04/13/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DSRLF News and Ratings via Email

Sign-up to receive the latest news and ratings for DSRLF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

DiaSorin (OTCMKTS:DSRLF) Frequently Asked Questions

Is DiaSorin a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DiaSorin in the last year. There are currently 4 sell ratings, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" DiaSorin stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DSRLF, but not buy additional shares or sell existing shares.
View analyst ratings for DiaSorin
or view top-rated stocks.

What stocks does MarketBeat like better than DiaSorin?

Wall Street analysts have given DiaSorin a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but DiaSorin wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is DiaSorin's next earnings date?

DiaSorin is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for DiaSorin

How has DiaSorin's stock been impacted by Coronavirus (COVID-19)?

DiaSorin's stock was trading at $122.5186 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DSRLF stock has increased by 47.5% and is now trading at $180.7333.
View which stocks have been most impacted by COVID-19

Who are DiaSorin's key executives?

DiaSorin's management team includes the following people:
  • Mr. Carlo Rosa, CEO, GM & Exec. Director (Age 55)
  • Dr. Chen Menachem Even, Chief Commercial Officer, Sr. Corp. VP of Commercial Operations & Exec. Director (Age 58)
  • Mr. Piergiorgio Pedron, Corp. Accounting Documents Officer, CFO & Sr. Corp. VP (Age 50)
  • Mr. Riccardo Fava, Sr. Director of Investor Relations & Corp. Communication
  • Mr. Marco Minolfo, Mang. of the Corp. Legal Affairs Department
  • Mr. Stefano Ronchi, Sr. Corp. VP of HR (Age 61)
  • Mr. Ugo Gay, Sr. Corp. VP of Industrial Operations (Age 56)
  • Mr. John D. Gerace, Pres of DiaSorin Molecular LLC

Who are some of DiaSorin's key competitors?

What is DiaSorin's stock symbol?

DiaSorin trades on the OTCMKTS under the ticker symbol "DSRLF."

How do I buy shares of DiaSorin?

Shares of DSRLF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DiaSorin's stock price today?

One share of DSRLF stock can currently be purchased for approximately $180.73.

How much money does DiaSorin make?

DiaSorin has a market capitalization of $10.11 billion and generates $791.17 million in revenue each year. The company earns $196.82 million in net income (profit) each year or $3.59 on an earnings per share basis.

How many employees does DiaSorin have?

DiaSorin employs 1,876 workers across the globe.

What is DiaSorin's official website?

The official website for DiaSorin is www.diasoringroup.com.

Where are DiaSorin's headquarters?

DiaSorin is headquartered at Via Crescentino, Saluggia L6, 13040.

How can I contact DiaSorin?

DiaSorin's mailing address is Via Crescentino, Saluggia L6, 13040. The company can be reached via phone at 390-161-4871 or via email at [email protected]

This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.